Drugs / BBT-401-1S
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04478825 | Jun → Aug 2021 | ulcerative colitis | Bridge Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03482648 | Mar → Sep 2018 | ulcerative colitis | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04596293 | Jun 2021 → May 2022 | ulcerative colitis | Bridge Biotherapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT03800420 | Apr 2019 → May 2020 | ulcerative colitis | Bridge Biotherapeutics, Inc. | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-01-16 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical enters into new drug candidate ‘BBT-401’ joint development and technology transfer contract with Bridgebio daewoong.co.kr ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBT-401-1S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03482648 ↗ |
| Known as | BBT-401 | “* Induction Phase: BBT-401 800mg for 8 weeks” NCT04596293 ↗ |
| Modality | Peptide | “Novel Oral Peptide BBT-401-1S” NCT03482648 ↗ |
| Route | Oral | “Single dose of BBT-401-1S, 7 dose levels, oral capsule” NCT03482648 ↗ |